Corrigendum to "The cost of multiple sclerosis in Australia" [Journal of Clinical Neuroscience 14 (2007) 532-539] (DOI:10.1016/j.jocn.2006.08.007);The cost of multiple sclerosis in Australia

Journal of Clinical Neuroscience

Volumn 14, Issue 6, 2007, Pages 532-539

  Taylor, Bruce ^a   McDonald, Elizabeth ^b   Fantino, Bruno ^c   Sedal, Les ^d   MacDonnell, Richard ^e   Pittas, Fotini ^a   Groom, Trish ^a  

^a ROYAL HOBART HOSPITAL   (Australia)

^b MS Society of New South Wales Victoria   (Australia)

^c Association pour le Développement de l'Information Médicalisée   (France)

^d ST VINCENT S HOSPITAL   (Australia)

^e AUSTIN HEALTH   (Australia)

Author keywords

Direct costs; Indirect costs; Interferon beta; Multiple sclerosis; Primary progressive; Relapsing remitting; Secondary progressive

Indexed keywords

IMMUNOMODULATING AGENT;

ADULT; AGED; ARTICLE; AUSTRALIA; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITALIZATION COST; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NURSING; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 34147109108     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2007.11.004     Document Type: Erratum

References (23)

1. Amato M.P., Battaglia M.A., Caputo D., et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249 (2002) 152-163
2. Asche C.V., Ho E., Chan B., et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 95 (1997) 268-274
3. Battaglia M.A., Zagami P., and Uccelli M.M. A cost evaluation of multiple sclerosis. J Neurovirol 6 Suppl.2 (2000) S191-S193
4. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part I: Cost of illness. Can J Neurol Sci 25 (1998) 23-30
5. Bourdette D.N., Prochazka A.V., Mitchell W., et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch Phys Med Rehabil 74 (1993) 26-31
6. Inman R.P. Disability indices, the economic costs of illness, and social insurance: the case of multiple sclerosis. Acta Neurol Scand Suppl 101 (1984) 46-55
7. Grudzinski A.N., Hakim Z., Cox E.R., et al. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics 15 (1999) 229-240
8. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
9. Johnson K.P., Brooks B.R., Cohen J.A., et al. Epidemiology of multiple sclerosis: a critical overview. Copolymer 1 Multiple Sclerosis Study Group. Can J Neurol Sci 20 (1993) 17-29
10. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
11. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
12. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
13. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56 (2001) 1628-1636
14. Johnson K.P., Brooks B.R., Cohen J.A., et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50 (1998) 701-708
15. Johnson K.P., Brooks B.R., Ford C.C., et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6 (2000) 255-266
16. Paty P, Kappos L, Stam Moraga M, et al. Long-term observational efficacy and safety follow-up of the PRISMS cohort. 19th Congress of the European Committee and Research in Multiple Sclerosis. Milan, Italy, 2003; P555.
17. Henriksson F., Fredrikson S., Masterman T., et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 8 (2001) 27-35
18. The National Institute for Clinical Excellence. Framework Document. National Health Services of the UK: London; 2004.
19. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
20. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50 (2001) 121-127
21. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (1996) 907-911
22. Patwardhan M.B., Matchar D.B., Samsa G.P., et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 11 (2005) 232-239
23. Whetten-Goldstein K., Sloan F.A., Goldstein L.B., et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 4 (1998) 419-425